This study evaluated the effect of diabetic control on achieving sustained virologic response in patients with chronic hepatitis C virus infection who received direct-acting antivirals (Daclatasvir + Sofosbuvir ± Ribavirin). It included 100 patients with chronic HCV infection (Treatment naive patients). Patients were classified into 3 groups according to diabetic control; GI: non diabetics, GII: well controlled diabetics & GIII: poorly controlled diabetics. All were subjected to clinical and laboratory examinations, abdominal ultrasonography and calculation of FIB-4 score. PCR for HCV RNA was assessed prior to treatment, post treatment and 12 weeks post-treatment. The results showed insignificant differences between all groups as regards sustained virologic response. Overall sustained virologic response was achieved in 91% of patients including 91.8% of patients treated with Daclatasvir + Sofosbuvir and 89.7% of those treated with Daclatasvir + Sofosbuvir + Ribavirin.